Scientific Program Committee

Wednesday
February 6 Sessions
Session 44 CROI 2008
e Wednesday, 4-6 pm; Ballroom B/C
Session 44–Symposium CME
Frontiers in Vaccine Research
151
Advances in Vaccines Scaffolds
Bill Schief
Univ of Washington, Seattle, US
Conveners:
David Ho, Aaron Diamond AIDS Res Ctr,
The Rockefeller Univ, New York, NY, US
Lynn Morris, Natl Inst for Communicable
Diseases, Johannesburg, South Africa
152
Lessons Learned from HIV-1 Envelope Glycoprotein
Immunogenicity Analysis
M Forsell 1,2 , B Dey 1 , A Moerner 3 , G Voss 4 , R Thorstensson 3 ,
P Kwong 1 , G Shaw 5 , J Mascola 1 , G Karlsson Hedestam 2,3 , and
Richard Wyatt* 1
1 Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US; 2 Karolinska
Inst, Stockholm, Sweden; 3 Swedish Ctr for Infectious Disease
Control, Solna; 4 GlaxoSmithKline, Rixensart, Belgium; and
5 Univ of Alabama at Birmingham, US
153
Identification and Characterization of Transmitted
and Early Founder Viruses in Primary HIV-1 Infection
B Keele 1 , E Giorgi 2,3 , J Salazar-Gonzalez 1 , F Gao 4 , R Swanstrom 5 ,
M Busch 6 , B Haynes 4 , B Korber 2,7 , B Hahn 1 , and George Shaw* 1
1 Univ of Alabama at Birmingham, US; 2 Los Alamos Natl Lab,
NM, US; 3 Univ of Massachusetts, Amherst, US; 4 Duke Univ,
Durham, NC, US; 5 Univ of North Carolina at Chapel Hill, US;
6 Blood Systems Res Inst, San Francisco, CA, US; and 7 Santa Fe
Inst, NM, US
154
Attenuated SIV Models and Protection from
Pathogenic Heterologous Challenges
James Hoxie* 1 , A Jordan1 , B Haggarty1 , J Romano1 , M Piatak2 ,
J Lifson2 , D Montefiori3 , M Marsh4 , and P Fultz5 1 2 Univ of Pennsylvania Sch of Med, Philadelphia, US; NCI-
Frederick, MD, US; 3Duke Univ, Durham, NC, US; 4Univ Coll
London, UK; and 5Univ of Alabama at Birmingham, US
Objectives: This session is directed to clinicians and scientists interested in
immunology and vaccine development. It is assumed that participants are
familiar with basic HIV biology, acute infection, principles of cellular and
humoral immunology, and how antibodies recognize foreign antigens. At the
completion of the session, participants will be knowledgable about how HIV
evades the early immune response to HIV during acute infection, animals
models of vaccine-induced protection against disease progression, problems
associated with eliciting neutralizing antibodies against HIV, and some of the
promising strategies to overcome these roadblocks. In particular, the promise
and limitations of rational vaccine design, and how those such vaccines are
evaluated, will be better understood.
24 15th Conference on Retroviruses and Opportunistic Infections
e Wednesday, 4-6 pm; Auditorium
Session 45–Symposium CME
Individualizing Patient Management
Conveners:
Elly Katabira, Makerere Univ, Kampala,
Uganda
Caroline Sabin, Royal Free and Univ Coll
Med Sch, London, UK
155
Optimizing Patient Management in Resource-limited
Settings
Jonathan Mermin
CDC Kenya, Nairobi
156
Individualizing Patient Management: Host Genetics
Jacques Fellay
Duke Univ, Durham, NC, US
157
Individualized Management of Therapy: Virologic
Complications
Carlo-Federico Perno
Univ of Rome Tor Vergata, Italy
158
Individualized Management of Therapy: The Issue
of Complications
Jennifer Hoy
Alfred Hosp, Monash Univ, Melbourne, Australia
Objectives: This session is directed to clinicians and scientists interested
in gaining an understanding of the optimal management of HIV-infected
patients. The session will address this issue in a global context. It is assumed
that participants are familiar with natural history of HIV infection and basic
principles of HIV management. At the completion of the session, participants
will be able to identify key host-related factors, virological consideration,
and patient complications that determine outcome of HIV/AIDS. Participants
will also gain a better understanding of individual management strategies in
resource-limited settings.